NASDAQ$TMDX

TransMedics Group Inc · Q1 2018 earnings

Q1 2018 earnings · · Investor relations

Headline financials

Total Revenue

$2.52M

Previous: $1.86M+35.7%
EPS (adj)

-$0.34

Previous: -$1.22+72.3%
Net Income

-$4.9M

Previous: -$5.68M+13.8%
Operating Income

-$4.78M

Previous: -$5.6M+14.6%
Gross Profit

$924K

Previous: $562K+64.6%
R&D Expense

$3.47M

Previous: $4.08M-15.0%

Revenue & EPS history

TransMedics · Revenue · Quarterly

$2.52M

Q1 2018+35.7%vs Q1 2017
Beat estimate in 4 of 7 quarters(57%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports

Historical avg

+4.1%

Avg return

Earnings day

+2.3%

Avg return

5 days after

+7.6%

Avg return

30 days after

54%

15 / 28 earnings

Positive

+42.6%

Q3 2023

Best reaction

-29.3%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.1%-30.0%-26.4%
Q4 2025-4.6%-3.6%-35.1%
Q3 2025+0.9%-9.0%+8.9%
Q1 2025+19.6%+31.3%+49.2%
Q4 2024+5.8%-6.5%-4.9%
Q3 2024-29.3%-34.2%-30.4%
Q2 2024+9.4%+7.2%+21.4%
Q1 2024+20.9%+31.6%+40.3%
Q4 2023+6.7%-0.5%-10.8%
Q3 2023+42.6%+34.6%+73.5%
Q2 2023-8.9%-24.7%-21.5%
Q1 2023-6.7%-6.4%-8.1%
Q4 2022+20.2%+20.4%+15.4%
Q3 2022+20.7%+17.6%+38.7%
Q2 2022-7.7%+20.8%+28.9%
Q1 2022+39.5%+25.4%+29.5%
Q4 2021+23.2%+39.5%+82.5%
Q3 2021-12.0%-16.3%-29.0%
Q2 2021+9.6%+7.6%+17.2%
Q1 2021-12.6%-15.1%-11.3%
Q4 2020+3.4%-12.3%+10.6%
Q3 2020+4.8%+10.6%+20.8%
Q2 2020+0.1%-3.2%-11.9%
Q1 2020-7.6%-0.6%-11.7%
Q4 2019-1.1%-1.2%-25.7%
Q3 2019-14.2%-13.0%-1.7%
Q2 2019-4.2%-4.6%+8.6%
Q1 2019-2.3%-2.1%-4.1%
Q4 2018
Q3 2018
Q2 2018
Q1 2018
Q4 2017
Q3 2017
Q2 2017
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro